India, July 8 -- Quanterix Corporation (QTRX), a leader in ultra-sensitive biomarker detection, has completed its acquisition of Akoya Biosciences, Inc., a strategic move that positions the combined company as a leading force in early disease detection across neurology, oncology, and immunology.
Per the amended merger agreement announced on April 29, Quanterix issued approximately 7.8 million shares of its common stock and paid around $20 million in cash to Akoya shareholders and equity holders. The acquisition is expected to expand Quanterix's total addressable market from $1 billion to $5 billion by integrating blood and tissue-based biomarker solutions for a more comprehensive disease detection platform.
Quanterix CEO Masoud Toloue sta...